[ad_1]
About the speakers
Dr. Kizmekia Corbett, Lead Scientist, Covid-19 mRNA Vaccine Development; Assistant Professor, Harvard TH Chan School of Public Health
Dr. Kizmekia Corbett was the scientific leader of the Corona Virus Group at the US National Institutes of Health’s Vaccine Research Center, where she studied coronavirus biology and vaccine development. Those 6 years of research led to the breakthrough discovery that a stable version of the spike protein found on all coronaviruses could be a prime target for vaccines, treatments and diagnostics. Early in the Covid-19 pandemic, she and her colleagues were central to the development of the Moderna mRNA vaccine and Eli Lilly’s therapeutic monoclonal antibody, both of which were the first in the world to enter clinical trials. As a result, her work is having a major impact on ending the worst respiratory disease in more than 100 years. Dr. Corbett is now an Assistant Professor in the Division of Immunology and Infectious Diseases at the Harvard TH Chan School of Public Health, as well as a Schutzer Assistant Professor and Philip T. Associate Fellow at the Harvard Radcliffe Institute for Advanced Study. Susan M. Ragon Institute. Her work now extends beyond the rapid development of Covid-19 vaccines to a view of this pandemic and future viral outbreaks.
Perhaps as much as her scientific achievements, Dr. Corbett entered the public arena in the face of world-changing gifted scientists. She is a star science communicator who explains the vaccine and the virus in a very accessible way to the media, two US presidents and audiences around the world.
Laurent Duvernay-Tardif, Graduated in Medicine; Super Bowl Champion
Laurent DuVernay-Tardif, dubbed “the most interesting man in the NFL,” is an eight-year NFL veteran, a Super Bowl champion, and the only active NFL player with a medical degree. Months after winning the Super Bowl with the Kansas City Chiefs — and in the midst of the Covid-19 pandemic — DuVernay-Tardif stepped away from football and joined the medical front. From the incredible heights of winning the Superbowl to burnout, DuVernay-Tardiff shares his remarkable personal story, talks about recovery, leadership and more.
As plans for the 2020 NFL season ramped up, DuVernay-Tardiff pulled out of his favorite game, becoming the first player to officially opt out of the 2020 NFL season. For the first time in his illustrious career, the DuVernay-Tardif twins were unable to reconcile their passions for football and medicine, and found themselves on the front lines of an epidemic months after the team’s Super Bowl win. Long-term care facility in Quebec. While working on the front lines, DuVernay-Tardif enrolled at Harvard’s TH Chan School of Public Health.
Juergen Eckhardt, SVP and Head, Leaps by Bayer
Juergen Eckhardt is SVP and head of Bayer Lips, Bayer’s impact investing division. Lips’ mission is to invest in technology and disruptive business models in the healthcare and agriculture sectors. Juergen has been a venture investor since 2002 and currently serves on the boards of Join Bio, Dewpoint, Century, Chloris, Ort Bio, Immunitas, Egenesis and others. Previously, Juergen was with McKinsey & Co. He was a management consultant and associate partner and a member of McKinsey’s healthcare leadership team. He started his career as a radiologist at Basel University Hospital in Switzerland. Juergen received his M.D. from the University of Basel and his MBA from INSEAD in Fontainebleau, France.
Elizabeth Bramson-Boudreau, CEO and Publisher, MIT Technology Review
Elizabeth Bramson-Boudreau is CEO and publisher of the Massachusetts Institute of Technology, an independent media company.
In the year Since Elizabeth took the helm of MIT Technology Review in mid-2017, the business has transformed from a respectable but excellent print magazine to a widely read, multi-platform media brand with a global audience and sustainable business. . Under her leadership, MIT Technology Review has been praised for its editorial authority, best-in-class events, and independent use of original research to support new advertisers and readers.
Elizabeth has 20 years of experience building and running teams at the world’s leading media companies. She has a strong focus on innovative ways to market media content to appeal to discerning, inquisitive consumers as well as B2B audiences.
Prior to joining MIT Technology Review, Elizabeth held senior executive roles at The Economist Group, where her leadership spanned business lines and included mergers and acquisitions. Innovation and modernization of editing and production; sales; Marketing: and events. In the past, she has worked as a consultant advising technology companies on market penetration and international expansion.
Elizabeth holds an MBA from the London Business School, an MSc from the London School of Economics, and an undergraduate degree from Swarthmore College.
[ad_2]
Source link
